2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
4 citations
,
March 2003 in “International Journal of Dermatology” Pimozide treatment resolved cysts and partially restored cheek fat in a man with Barraquer–Simons syndrome.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
11 citations
,
October 1941 in “Experimental Biology and Medicine” PABA helps prevent gray hair and hair loss in mice.
16 citations
,
June 2016 in “Innovare Academic Sciences - Innovare Journal of Ayurvedic Sciences” Bacopa monnieri is a herb used in traditional Indian medicine to enhance memory and treat various conditions.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
11 citations
,
September 2021 in “American Journal of Medical Genetics Part A” Four new cases of Bachmann-Bupp syndrome suggest potential for targeted treatment.
July 2013 in “Journal of clinical & experimental dermatology research” Bimatoprost can help treat hair loss.
April 2022 in “Reactions Weekly”
1 citations
,
February 1976 in “JAMA” Haloperidol effectively treated hemiballismus, but spontaneous improvement wasn't ruled out; rapid weight loss can cause hair loss with good regrowth chances.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
July 2010 in “Hair transplant forum international” The ABHRS held a test in Capri, Italy.
April 2023 in “Journal of Investigative Dermatology” Narrowband Ultraviolet B treatment can significantly reduce anxiety in psoriasis patients, but it doesn't significantly affect depression.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
May 2023 in “Elsevier eBooks” Minoxidil, finasteride, and dutasteride are treatments for hair loss.
1 citations
,
April 2025 in “American Journal of Medical Genetics Part C Seminars in Medical Genetics” Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.
January 2007 in “Journal of The American Academy of Dermatology” Hair tonic helps stop hair loss in most users.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
6 citations
,
December 2008 in “Clinics in Dermatology” Escitalopram might effectively treat delusions of parasitosis and possibly Morgellons disease, with psychological factors being important to consider.
May 1997 in “Hair transplant forum international” The document's conclusion cannot be summarized because the content is not accessible.